1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Tiansheng Pharmaceutical Group Co. Ltd. Class A

Tiansheng Pharmaceutical Group Co. Ltd. Class A

SSZSE:002872
5.53
CNY
-0.03
(-0.54%)
-0.19EPS
1.43BMarket Cap
Tiansheng Pharmaceutical Group Co. Ltd. Class A
SZSE:002872
(Shenzhen Stock Exchange)

Recent

price

5.53

P/E

ratio

- -

div

yld

0.84%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
4.99
6.7
7.62
7.74
8.74
7.74
6.83
5.26
3.78
2.32
1.91
1.82
1.79
1.62
1.62
Revenue per Share
0.55
0.59
0.75
0.81
0.94
0.52
0.24
-0.72
-1.54
-0.21
-0.28
-0.29
-0.27
-0.17
-0.18
Basic EPS, GAAP
-0.2
-0.33
-0.63
-0.26
0.34
-3.14
-0.3
0.16
0.31
-0.3
0.05
-0.32
- -
0.05
- -
Free Cash Flow per Basic Share
0.1
0.14
0.17
0.13
0.15
0.12
0.29
0.11
0.12
0.07
0.05
0.05
0.05
0.05
0.05
Dividend per Share
3.87
4.38
5.82
6.63
7.57
9.67
9.71
9.01
7.36
7.15
6.86
6.58
6.31
6.14
6.06
Book Value per Share
2.68
3.2
4.52
5.07
5.9
8.24
8.28
7.63
6.19
6.12
5.86
5.6
5.41
5.32
5.26
Tangible Book Value per Share
201
212
218
238
239
292
318
320
318
318
318
318
318
318
318
Basic Weighted Avg Shares
1,004
1,422
1,664
1,843
2,087
2,261
2,171
1,680
1,203
737
607
579
570
514
515
Sales/Revenue/Turnover
12.3
13.35
13.11
14.38
13.95
12.24
8.52
-6.13
-7.96
-4.53
-10.61
-11.15
-9.02
-7.44
-9.19
Operating Margin (%)
35
49
60
66
74
95
109
107
117
90
108
107
109
122
- -
Depreciation Expense
110
126
165
192
224
152
77
-229
-491
-68
-91
-93
-87
-55
-59
Net Income, GAAP
13.48
21.24
13.22
18.37
15.48
23.49
20.43
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
10.95
8.86
9.89
10.42
10.76
6.72
3.53
-13.65
-40.8
-9.2
-14.92
-16.07
-15.34
-10.78
-11.37
Profit Margin (%)
120
282
264
209
144
691
637
434
401
448
261
236
343
264
166
Working Capital
30
105
57
15
10
27
14
14
129
165
31
62
197
138
28
LT Debt
952
1,078
1,431
1,629
1,859
3,133
3,154
2,922
2,390
2,279
2,188
2,096
2,014
1,959
1,934
Total Equity
- -
8.45
8.67
8.2
8.47
5
2.63
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
10.24
10.9
10.25
10.33
5.13
2.65
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
12.8
13.53
12.93
13.26
6.23
2.49
-7.7
-18.86
-2.94
-4.06
-4.36
-4.27
-2.8
-2.99
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
221
345
297
LT Borrowings
137
17
26
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
318
318
318
Market Capitalization
1,545
1,600
1,428

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
680
663
641
Cash, Cash Equivalents & STI
280
266
271
Accounts Receivable, Net
113
103
97
Inventories
101
96
95
Total Current Liabilities
416
514
474
Payables & Accruals
- -
- -
- -
ST Debt
221
345
297
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.83%
-3.9%
-2.76%
Free Cash Flow
-1,565.22%
-2,805.59%
-12,870.59%
Net Income, GAAP
-44.22%
-18.51%
-36.59%
Sales/Revenue/Turnover
-10.58%
-14.47%
-9.76%
Total Cash Common Dividend
5.14%
-15%
-1.88%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
148
133
121
167
570
2025
116
117
- -
165
514
2026
132
101
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
-0.07
0.02
-0.16
-0.27
2025
-0.04
-0.08
- -
-0.03
-0.17
2026
-0.03
-0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.05
2025
0.01
0.01
- -
0.01
0.05
2026
0.01
0.01
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tiansheng Pharmaceutical Group Co., Ltd. operates in the pharmaceutical sector, engaging in the research, development, production, and distribution of medicines. The company offers an extensive range of products, including traditional Chinese and chemical drugs, covering therapeutic areas such as respiratory, digestive, cardiovascular, pediatric, gynecological, orthopedic, oncology, and metabolic systems. Its business scope also extends to the cultivation and processing of Chinese herbal medicines. Established in 2001, the company is headquartered in Chongqing, China.